Translational Clinical Pharmacology Research in Drug ... · Translational Clinical Pharmacology...
Transcript of Translational Clinical Pharmacology Research in Drug ... · Translational Clinical Pharmacology...
PROGRAM
South Asian Chapter of American College of Clinical Pharmacology
8th International Annual Conference
Translational Clinical Pharmacology Research in
Drug Development
Pre Conference Workshop Date: 23rd April 2015
Conference Dates: 24th- 25th April 2015
Venue: Nehru Centre, Dr Annie Besant Rd, Worli, Mumbai, India.
8th Annual Conference Highlights:
The Theme of 8th Annual Conference of SAC-ACCP is - Translational Clinical Pharmacology for Drug Development. Needless to state, drug development for local-regional health needs is a very important topic for India and the South East Asia region. There are two parallel track pre-conference workshops – one in Clinical Pharmacology /translation of PK/PD of Anti-infective drugs and the other in Medical writing taking into consideration needs of young researchers and the Industry. A conscious decision was taken by the organizing committee in this edition of the annual conference to concentrate on translational Clinical Pharmacology of both Infectious diseases (Tuberculosis, Malaria) and Non Communicable diseases (Diabetes Mellitus, Oncology) from the perspective of Public health Importance in the South East Asia region. Every researcher would agree that ultimately, medical research must translate into improved treatments or treatment regimens for patients. The Organizing committee has been fortunate to have eminent faculty from Academia, Government and the Industry who have agreed to speak on their work in the chosen field and also provide information on how collaborations between different stakeholders are enabling development of better health care, improved quality of life, and enhanced treatment for patients. The faculty will enlighten the audience on how findings in the laboratory are getting translated into drug development and how it all goes into producing changes in clinical practice, from bench to bedside. International Faculty: Dr Meibohm Bernd Prof. Mark Atkinson Dr. Gangadhar Sunkara Dr Michael Conlon Dr Stephan Chalon Dr Peter K Hoffmann Dr Barbara Werner Dr Dakshina Chilukuri National Faculty: Dr M.K. Bhan Prof.DK Kochar Dr Kavita Singh Dr. Soumya Swaminathan Dr Umesh Gupta Dr Manoj Nesari Dr Subramanian Ganesan Dr Ayyappa Chaturvedula Dr. Rama Sivasubramanian Dr Praveen Myneni Dr Suhasini Sharma Dr Nithya Gogtay Dr AjithKumar Vasudevan Ms Dilmaher Guzder Dr. Rajesh Naik Dr Suhas Pingle Dr Jay Prakash Jain Dr Madhav Marathe Dr Bobby George Dr M Joseph
We have also recieved approval for four MMC credit points for the conference
Preconference workshop - I
Application of Translational Pharmacokinetics (PK)/Pharmacodynamics (PD) Principles in the Development of Anti-infective drugs
Day 1: Thursday, 23rd April 2015
Venue: Hall of Harmony
08.00am-09.00 am Registration/ Breakfast
09.00am-09.15am
Opening Remarks Orientation to workshop
Dr. Kiran Marthak, Member of Board of Directors and Global Head - Clinical Development, Lambda Therapeutics, Ahmedabad
Workshop Director:
Dr. Gangadhar Sunkara, Novartis Institute for Biomedical Research, USA
09.15am-10.00am
Drug exposure- Drug response relationship Concepts: Anti-bacterial drugs (Bacterial replication kinetics, Drugs review, PK-PD modeling)
Dr. Gangadhar Sunkara
10.00am- 10.45am In vitro models, Animal models and early stage clinical development translation of anti-bacterial drugs: 2 case examples
Dr Subramanian Ganesan, Novartis Healthcare Ltd, India
10.45am-11.00am Tea
11.00am-11.45am
Application of NLME Approaches in Pre-
Exposure Prophylaxis (PrEP) of HIV infection Dr Ayyappa Chaturvedula, GVK Life sciences, India
11.45am- 12.30pm “Dengue Nucleoside Antivirals:
Biopharmaceutical and PK/PD Challenges”
Dr. Rama Sivasubramanian, Novartis Healthcare Ltd., India
12.30pm-01.45pm Lunch
1.45pm -3.15pm
2- Case Studies for participants to work on (One nucleoside and on anti-TB drug case study) 15 min – review of cases 75 min – Breakouts
All faculty to be involved
3.15pm-3.30pm Tea
3.30pm -5.00pm 30 min – team presentations (each team) All faculty to be involved
Preconference workshop - II
Enhancing Skills in Medical Writing
Day 1: Thursday, 23rd April 2015 Venue: Hall of Culture
08.00 am-09.00 am Registration/Breakfast
09.00 am-09.15 am Opening remarks
Orientation to workshop
Dr Nilima Kshirsagar, ICMR, Mumbai
India
Workshop Director: Dr Padmaja Marathe ,Seth G S Medical College and KEM Hospital, Mumbai, India
09.15am-09.45 am Medical Writing: Scope and Skills Dr Suhasini Sharma, Director, Medical Affairs, Sciformix, Pune, India
9.45am-10.45am Critical Appraisal:1
All faculty
10.45am-11.00am Tea
11.00am-12.30pm Critical Appraisal:2
All faculty
12.30pm-1.45pm Lunch
1.45pm-2.15pm From the desk of an editor Dr Nithya Gogtay, Journal of Postgraduate Medicine, Mumbai, India
2.15pm-2.35pm Publication ethics Dr AjithKumar Vasudevan Novartis Limited., Hyderabad, India
2.35pm-3.15pm Safety writing in the pharmaceutical industry
Dr. Supriya Desai, Sciformix Corporation, Mumbai, India.
3.15pm-3.30pm Registration/Breakfast
3.30pm-4.15pm The Art and Science of Writing an SAE narratives (15 min) Team presentations (30 min)
Ms Dilmaher Guzder Lead Medical Writer and Writing Coach, India
4.15pm- 4.35pm 4.35pm- 5.00pm
Ethical Advertising 1. Pharmaceutical advertising
2. Advertising by Medical Practitioners
Dr. Rajesh Naik, Head, Medical Affairs Boehringer Ingelheim, Mumbai Dr Suhas Pingle, Mumbai
5.00pm-5.15pm Open House and participant feed back Concluding remarks
Dr Padmaja Marathe,Mumbai Prof. YK Gupta, AIIMS, Delhi
Main Conference
Day 2: Friday, 24
thApril, 2015
Venue: Hall of Culture
07.30am-8.00am Registration and Breakfast
08.00am-9.30am
Session 1: ORAL/POSTER PRESENTATIONS
Session 1a: Clinical-Oral
Hall of Culture Presentation No: CL/OR/01 to
CL/OR/06
Chairpersons: Dr. Renuka Kulkarni - Munshi
Session 1b: Pre-Clinical-Oral
Hall of Harmony Presentation No: PR/OR/01 to PR/OR
/06
Chairperson: Dr. Geeta Vanage
POSTERS
Session 1c: Clinical Poster Evaluation (CL/P)
Session 1d: Pre-Clinical Poster Evaluation (PR/P)
9.30am-10.30am
Session 2: INAUGURATION
by
Dr. BK Goyal, Dr. Anil Kakodkar and Dr. GB Parulkar
Felicitation of Dr V. M. Katoch, Dr M. K. Bhan, Dr Ram Vishwakarma (CDRI),
Mr Pankaj Patel, Mr Glenn Saldhana and Mr Dilip Shanghvi
10.30am-11.30am
Session 3 : KEY NOTE ADDRESS
Chairpersons: Dr A.S Nanivadekar and Dr Michael Conlon
10.30am-11.00am Role of clinical pharmacology discipline in drug discovery and development to improve the healthcare of patients
Dr M.K. Bhan, IIT, New Delhi, India
11.00am-11.30am State-of-the-art Science in clinical pharmacology to support drug discovery and development: vision 2020
Dr Meibohm Bernd, President, ACCP,USA
11.30am- 11.50am Tea
11.50am-1.30pm Session 4: TRANSLATIONAL EFFICACY
Chairpersons: Dr V P Kamboj and Dr Kiran Marthak
11.50am-12.10pm
“Keynote presentation” Are we getting the dose right in late stage clinical trials? – Lost in Translation? (Differences in clinical biomarkers from Diabetes perspective)
Prof. Mark Atkinson, Univ. of Florida, FL, USA
12.10pm-12.30pm Challenges in translating efficacy between animal models and humans:(Oncology Case Study)
Dr Praveen Myneni, NATCO, Hyderabad, India
12.30pm-12.50pm FDA Critical Path Initiative – Translational Research!
Dr Michael Conlon, Univ. of Florida, FL, USA
12.50pm-1.10pm Translational research with Anti hyperglycemic agents Indian perspective
Dr Vyankatesh Shivane, Seth GSMC & KEMH, Mumbai,India
1.10pm-1.30 pm Q&A
1.30 pm-2.30pm Lunch
2.30pm-4.10pm
Session 5: TRANSLATIONAL CLINICAL PHARMACOLOGY
RESEARCH IN THE DEVELOPMENT OF ANTI-MALARIA DRUGS
Chairpersons: Dr Ashok Vaidya and Dr Jayanthi S Shastri
2.30pm-2.50pm Why is malaria still a dangerous disease? Epidemiological and microbiological perspective
Prof.DK Kochar, RUHS College of Medical Sciences, Jaipur
2.50pm-3.10pm Translational aspects in Malaria Vaccine development
Dr Kavita Singh, Program Director, MVDP, New Delhi, India
3.10pm-3.30pm Combination drug development strategy to treat Malaria: PK-PD considerations
Dr Jay Prakash Jain, Novartis, Hyderabad, India
3.30pm-3.50pm
“Keynote presentation” An effective game plan to combat Malaria
through innovative drug discovery and
development: focus on translational clinical
pharmacology
Dr Stephan Chalon, MMV, Switzerland
3.50pm-4.10pm Q&A
4.10pm-4.30pm Tea
4.30pm-5.30pm
Session 6: PANEL DISCUSSION-TRANSLATIONAL RESEARCH IN
SOUTH ASIA AND USA
Moderators : Prof Nilima Kshirsagar and Dr Gangadhar Sunkara
Panelists: Dr T.S. Rao, DBT, Govt. of India; Dr Vipin Kumar, National
Innovation Foundation ; Dr O.P Agarwal, Ex- CSIR; Bejon Misra, Jago
Grahak Jago, Dr Rajendra Jani, Zydus Cadila and Dr Mahmed Salahuddin,
Bangladesh
5.30pm-6.30pm
Session 7: ORAL/POSTER PRESENTATIONS
Session 7a:Clinical-Oral
Presentation No: CL/OR/07 to CL/OR/16
Hall of Culture
Chairperson:
Dr. Taruna Gupta
Day 3: Saturday, 25th April 2015
Venue: Hall of Culture
7.30am-8.00am Registration and Breakfast
8.00am-9.30am Session 8: ORAL/POSTER PRESENTATIONS
Session 8a: Clinical-Oral
Hall of Culture
Presentation No:
CL/OR/17 to CL/OR/23
Chairpersons: Dr. Lalita Savardekar
Session 8b: Pre-Clinical-Oral
Hall of Harmony
Presentation No:
PR/OR/07 to PR/OR/14
Chairperson: Dr. Renuka Kulkarni - Munshi
POSTERS EVALUATION
Session 8c: Clinical Poster Evaluation (CL/P)
Session 8d: Pre-Clinical Poster Evaluation (PR/P)
9.30am-11.10am Session 9 : TRANSLATIONAL SAFETY
Chairpersons: Dr Gurumurthy Parthasarathy and Dr Dakshina Chilukuri
9.30am-9.50am Investigative Toxicology: Challenges in translating general toxicity data to early stage clinical safety studies
Dr Peter K Hoffmann, Novartis, USA
9.50am-10.10am Translating Liver Function across species: Future directions
Dr Madhav Marathe, Toxicologist, SPARC, Baroda, India
10.10am-10.30am
Translating Benefit/Risk Assessment between early and late stage clinical trials: Role of comedications, co-morbid disease conditions, Regions?
Dr Barbara Werner, Novartis, USA
10.30am-10.50am
Predictive value of preclinical safety studies: Challenges in translating cardiovascular safety pharmacology data to early stage clinical safety studies
Dr Peter K Hoffmann, Novartis, USA
10.50am-11.00am Q &A
11.00am-11.10am Tea
11.10 am-12.30 pm
Session 10 : TRANSLATIONAL CLINICAL RESEARCH IN THE
DEVELOPMENT OF ANTI-TUBERCULOSIS DRUGS
Chairpersons: Dr Amita Athavale and Dr Ameeta Joshi
11.10 am-11.30 pm
Key note Presentation: Is fighting MDR/XDR-Tuberculosis a difficult battle?: Epidemiological and microbiological perspective
Dr. Padmapriya Darsini, Scientist -E, National Institute
for Research in Tuberculosis, Chennai,India.
11.30 am-11.50pm In vitro and animal models to assess the efficacy of anti-tuberculosis drugs: Current advances in the field and future directions
Dr Umesh Gupta, JALMA, Agra
11.50 am-12.10pm Translational PK/PD strategy : Historical experience (preclinical to clinical translation) – Finding a right dose for Phase 2 studies
Dr Subramanian Ganesan, Novartis, India
12.10 pm-12.30pm Q & A
12.30 pm-1.30 pm Lunch
1.30 pm-1.50 pm
Key Clinical Pharmacology Aspects of TB Drug
Development Dr Dakshina Chilukuri, USA
1.50 pm-2.10 pm “Keynote presentation”
Ongoing fight against Tuberculosis - do we have enough army?
Dr Gangadhar Sunkara Novartis Institute for Biomedical Research, USA
2.10 pm-2.30 pm Q & A -
2.30 pm-3.30pm
Session 11: REGULATORY ASPECTS – TRANSLATION TO PUBLIC
HEALTH
Chairpersons: Dr Anish Desai and Prof. Nirmala Rege
2.30 pm-2.50 pm Traditional Medicine: challenges and opportunities in translational research
Dr Manoj Nesari, AYUSH, India
2.50pm-3.10pm Regulatory requirements for Bench to Bedside translation for drug discovery & development in India
Dr Bobby George, Reliance Clinical Research, Mumbai, India
3.10pm-3.30pm Translation of anti TB drugs from bench to Bedside - Lupin story
Dr M Joseph Lupin Pharma., Pune, India
3.30pm-3.50pm Tea
3.50pm-5.00pm Valedictory function
Dr Peter Hoffmann
Dr Praveen Mayneni
Dr Soumya Swaminathan
Dr Barbara Werner
Dr Hoffmann currently works at Novartis in
Preclinical Safety. He supports safety
evaluations for projects in cardiovascular and
metabolic indications and serves as Global
Preclinical Expert for Cardiovascular Safety
and co-chair of the Translational
Cardiovascular Advisory Team. He is an MD
and PhD from the Medical School at the Martin
Luther University in Halle, Germany
Dr Mayneni is currently Medical Officer &
Coordinator - Drug Development at
NATCO Pharma Ltd.
Dr Swaminathan is a Paediatrician by training,
having completed her medical education at the
Armed Forces Medical College and the All
India Institute of Medical Sciences (India)
followed by a fellowship in pediatric
pulmonology at the Children’s Hospital of Los
Angeles (USA). She is currently Director of the
centre and heads the NIH International Centre
for Excellence in Research.
Dr Werner is an American Board certified
Psychiatrist who has been in both Academia and
Industry in the domain of drug development. She
currently works as VP- Global Safety in Novartis
Pharmaceutical, USA.
Prof Umesh Gupta
Dr Bobby George
Dilmaher Guzder
Dr Madhav Marathe
Dr Gupta is currently Deputy Director/Scientist F
at the National JALMA Institute for Leprosy &
Other Mycobacterial Diseases based out of Agra,
India. He has been associated as PI and Co-PI in
number of projects funded by DBT and ICMR on
Leprosy and Tuberculosis
Dr. George is currently Vice President & Head
Regulatory Affairs, Reliance Life Sciences Pvt
Ltd. where he is responsible for providing
regulatory guidance and strategic inputs for their
Pharmaceutical, biopharmaceutical, and novel drug
development programs including stem cells to
assure appropriate and timely regulatory filing and
approvals, across different regions globally. He
holds a M. Pharm and Ph.D. in Pharmacology from
Panjab University, Chandigarh
Dilmaher Guzder is a Clinical Pharmacist with 16
years of work experience, including 8 years in the
international healthcare sector and about 8 years in
pharmacovigilance and medical writing. She has
completed M. Sc in Clinical Pharmacy (Hospital),
University of Bradford, UK. She is a Lead Medical Writer with expertise in
quality and editorial review of various types of
scientific, safety and regulatory documents and
training.
Dr Marathe is currently Vice President, Pre-
clinical Toxicology at Sun Pharma Advanced
Research Company Ltd, (SPARC), Vadodara. He
is a Masters in Veterinary Pathology (M.V.
Sc.)with distinction from Bombay University,
Toxicology & QA Certification form US-FDA and
also the Senior most Pre-clinical Toxicologist and
Pathologist in India, in New Drug Discovery
Research and NDDS with over 42 years of
experience
Dr Ajith Kumar Vasudevan
Dr Suhasini Sharma
Dr Nithya Gogtay
Dr Supriya Desai
Dr Vasudevan is currently Group Lead -
Medical Communications, Respiratory
Novartis Healthcare Private Limited Global
Medical and Clinical Services . He is a PhD
and a Project management professional
(CMPP).
Dr. Sharma is an MD who is currently the
Director, Medical Affairs at Sciformix
Technologies, a functional service provider
to global biopharmaceutical companies. She
provides medical expertise and guidance for
Company’s services in the areas of Scientific
Writing, Safety & Risk Management, and
Medical Affairs & Clinical Research
Dr Nithya Gogtay is currently working as
Additional Professor in the Department of
Clinical Pharmacology Seth GS Medical
College & KEM Hospital, Mumbai
(Bombay, India. She has over 100 peer
reviewed publications to her credit. She has
received special training in
Pharmacovigilance at the Uppsala
Monitoring Centre, Sweden. She is also
theEditor of the Journal of Postgraduate
Medicine and member of the Journal of
Association of Physicians of India.
Dr. Desai is a Clinical Research and
Pharmacovigilance (PV) Executive with
over 16 years of experience in clinical
practice and in various leadership roles in
clinical research, drug safety and PV. In her
current role as Practice Head and Medical
Director at Sciformix, she provides scientific
and operational leadership to a global team
of physicians and RNs involved in medical
review activities across pharmacovigilance,
safety writing, signal management and allied
safety surveillance activities, spanning
diverse therapeutic areas.
Dr Bernd Meibohm
Dr Dakshina Chilukuri
Dr Ayyappa Chaturvedula,
Dr Jay Prakash Jain
Bernd Meibohm, Ph.D. is serves as President
for the American College of Clinical
Pharmacology (ACCP) and is a Professor of
Pharmaceutical Sciences at the College of
Pharmacy, The University of Tennessee
Health Science Center, Memphis. His
scientific interests include pulmonary
infectious and inflammatory diseases,
pediatric pharmacotherapy and the
application of quantitative modeling and
simulation techniques in preclinical and
clinical drug development, with specific
focus on therapeutic proteins.
Dr Chilukuri is a Ph.D. in Pharmaceutical
Sciences from the Medical University of
South Carolina, Charleston, SC and
currently serves as Senior Clinical
Pharmacology Reviewer, Office of Clinical
Pharmacology, FDA, USA
Dr Chaturvedula, PhD. is currently General
Manager, Informatics and Analytics, GVK
Biosciences. He is a Pharmacometrics
scientist with pharmaceutical industry and
academic experience. Current research
interests are in mechanistic modeling,
population pharmacokinetic analysis
methods and quantitative pharmacology
Dr Jain is a PhD. from NIPER, Chandigarh,
India and currently works with Novartis
Institutes for biomedical research in the
Global Pharmacokinetics /
Pharmacodynamics division of the Drug
Metabolism and Pharmacokinetics (DMPK)
department. The current area of his work is
Clinical Pharmacology in Drug
Development with special focus on malaria
as dieses area.
Dr Kavita Singh
Dr. Mark Atkinson
Dr Michael Conlon
Dr Stephan Chalon
Dr Singh is currently Program Director,
Malaria Vaccine Development Program. She
is an MD (Microbiology) from PGI,
Chandigarh and has worked in academia,
government and Industry. She is a member of
Safety Monitoring Committees, Small
Business Innovation Research Initiative
(SBIRI) of department of biotechnology,
Project Monitoring Committee of various
projects of BIRAC.
Dr.Atkinson is currently the American
Diabetes Association Eminent Scholar for
Diabetes Research at The University of
Florida. He also serves as the Director for
the Diabetes Institute. Dr. Atkinson is an
internationally recognized authority on
multiple aspects pertaining to type 1
diabetes, with particular interests in disease
prediction and prevention, the role for
environment in the initiation of the disease,
stem cells and pancreatic regeneration, and
the identification of markers of tolerance and
immunoregulation.
Dr. Conlon is a Ph.D. in Statistics from the
University of Florida and currently serves as
Co-director of the University of Florida
Clinical and Translational Science Institute.
His responsibilities include strategic
program development, expansion and
integration of research and clinical
information resources, and strategic planning
for academic health and university research.
Dr Chalon is currently Medical Director –
Early Development & Clinical
Pharmacology at the Medicines for Malaria
Venture (MMV) based out of Geneva. He is
a PhD. in Pharmacology and has been with
Clinical Pharmacology drug development
groups across the industry in senior level
positions.
Dr BK Goyal
Dr Nilima Kshirsagar
Dr Anil Kakodkar
Dr G.B Parulkar
Padma Vibushan Dr Goyal is the honorary
dean and chief cardiologist at the Bombay
Hospital Institute of Medical Sciences and is
a former Director-Professor of cardiology of
JJ Group of Hospitals and Grant Medical
College, Bombay. Goyal is a visiting
professor of cardiology at the University of
Alabama, in USA and visiting cardiologist to
the Oschner Heart Institute, New Orleans.
He served as a member of the Executive
Council and Senate of the University of
Bombay for several years.
Dr Kshirsagar is National Chair Clinical
Pharmacology Indian Council of Medical
Research Govt. of India,Member DTAB and
President of SAC ACCP. Former Dean
&Director, GSMC KEM&H, Mumbai. She
has recieved several awards most notably Dr
BC Roy award and Vasvik award for
Industrial research and for societal
contribution and many others. Her research
interests include Infectious diseases, clinical
trials, drug development, therapeutic drug
monitoring, pharmacovigilance, She has
been the guiding force for developing an
indigenous version of Liposomal
Amphotericin.
Padma Vibushan Dr Kakodkar became the
Director of BARC in the year 1996 and
succeeded in developing various systems for
the pressurized heavy water reactors, in
building the Dhruva reactor starting from the
conceptual stage, in rehabilitation of Madras
Atomic Power Station Units. He played a
key role in nuclear tests in 1974 &1998 at
Pokhran. Kakodkar’s sterling leadership led
to a significant boost to India’s nuclear
power programme
Padma Vibushan Dr Parulkar is consultant
cardiovascular surgeon, former Dean &
Director Prof. & head dept. Cardiovascular
surgery, GSMC & KEM hospital, Mumbai.
Dr. Parulkar has carried out pioneering
clinical and scientific research in many areas
including extracorporeal circulation,
transmyocardial revascularization, and
several innovations in the techniques of
surgical management of patients with
complex congenital heart disease, correction
and replacement of valvular heart diseases
and coronary bypass surgery.
Dr Gangadhar Sunkara
Dr Joesph Marialouis
Dr MK Bhan
Dr T.S. Rao
Dr Sunkara is currently Executive Director
at Novartis Institute of Biomedical Research,
New Jersey, USA. Dr. Sunkara earned his
BS and MS in Pharmaceutical Sciences from
Kakatiya University in India and his PhD in
Pharmaceutical Sciences from the University
of Nebraska Medical Center in Omaha,
Nebraska. He has been a Lead
Pharmacokineticist in the Exploratory
Clinical Development division at Novartis
Pharmaceuticals.
Dr Marialouis is currently Assistant
Director, Clinical Operations, at Lupin
Bioresearch Center, Lupin Pharma ltd.,
Pune, India. He is a Clinical Research
Professional with 10 years of Industry
Experience in the conduct of
Bioavailability/Bioequivalence, 505b2, POC
& Clinical End point studies. He has a post
graduate degree in Pharmacology from
Madras Medical College.
Padma Bhushan Dr MK Bhan is National
Science Professor, IIT-Delhi and former
Secretary, DBT, Govt. of Inida.As
Pediatrician his areas of specialization are
pediatric gastroenterology, pediatric
infectious diseases and nutrition. He
developed rotavirus vaccine based on a
neonatal strain. Bhan developed low
osmolarity oral rehydration solution, which
has been introduced in the Diarrheal Disease
Control Programme by WHO and by the
Government of India.
Dr. T.S. Rao is Adviser in the Department of
Biotechnology, Ministry of Science &
Technology, Govt. of India. He is
coordinating the programs related to Medical
Biotechnology, Human Genetics & Genome
Analysis, National Bioethics Committee,
Vaccines Research and Development since
1988-89.Dr. Rao has also worked at National
Institute of Communicable Diseases, M/o
Health & FW, Govt. of India, in the area of
development of Malaria vaccine by using
molecular biology methods and developed
monoclonal antibodies for blood stages
of P.falciparum.
Dr Vipin Kumar
Bejon Misra
Dr Rajendra Jani
Dr Manoj Nesari
Dr Kumar is currently Director, National
Innovation Foundation-India, Department of
Science and Technology, Govt of India.
National Innovation Foundation-India is an
autonomous body of the Department of
Science and Technology, Government of
India, based on the Honey Bee Network
philosophy, which provides institutional
support to grassroots innovators and
outstanding traditional knowledge holders
from the unorganized sector of the society.
Bejon Misra has been in the consumer
movement in India for the last 25 years
starting from Jamshedpur in 1983 as the
founder of the Consumer Guidance Society
of Jamshedpur. He is a management
graduate with marketing as major from the
Banaras Hindu University. He has
professional experience for more than 35
years working as an entrepreneur. He is is at
present the Executive Director of a leading
consumer organisation, Voluntary
Organisation in Interest of Consumer
Education (VOICE) based in New Delhi.
Dr Jani is currently Senior VP, Clinical
R&D at Zydus Cadila Healthcare Ltd. He
has a doctorate in Pathology and
Bacteriology from faculty of medicine and
has more than 35 years’ experience. He has
conceptualized and conducted 35 “first in
man” (phase 1) studies with new chemical
entities and more than 180 phase ii – iv
clinical studies.He was responsible for
clinical research and development of two
new chemical entities; Miltefosine and
Saroglitazar.
Dr Nesari is currently Joint Adviser
(Ayurveda), Department of AYUSH
Ministry of Health & Family Welfare,
Government of India. He has 20 years
experience in the profession as Ayurveda
clinician during which, he has developed
expertise in Ayurvedic management of Pain
dominant conditions e.g. Spinal
Degenerative Diseases. His contribution
towards development of AYUSH Sector has
been varied in areas such as policy and
planning for matters pertaining to Ayurveda.
Dr Dhanpat Kumar Kochar
Dr Dhanpat Kumar Kochar is the founder
President of Tropical Neurology Subsection
of IAN. He has to his credit 165 publications
in national and international journals and 10
book chapters. He is the recipient of Second
Best Paper Award in JAPI twice and Best
referee award in 2008. His field of interest is
Malaria, Porphyria, Diabetic Neuropathy.
He is a reviewer of several journals
including The Lancet, Brain, PLoS One,
Emerging Infectious Disease, Epilepsia,
JAPI and Neurology India. He has received
several awards and invited orations in the
field of Malariology.
OUR SPONSORS
We gratefully acknowledge the support of our Sponsors for the pre-
conference workshop and the main conference.